-
EMD Serono Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 2025
22 May 2025 21:54 GMT
… decision-making.
Select EMD Serono-related abstracts accepted for … US Food and Drug Administration (FDA), and priority medicine (PRIME) … Information from the US FDA-Approved Label
BAVENCIO can … Guide.
About EMD Serono, Inc.
EMD Serono - the healthcare business …
-
Osteosarcoma Clinical Trials And Studies: EMA, PDMA, FDA Approvals, Mechanism Of Action, ROA, NDA, IND, And Companies
05 Mar 2025 02:39 GMT
(MENAFN- GetNews)
DelveInsight's,“ Osteosarcoma Pipeline Insight 2025 ” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Osteosarcoma pipeline landscape. It covers the Osteosarcoma pipeline drug profiles, including …
-
Merck KGaA's EMD Serono taps Selma Blair to join long-running campaign for MS drug Mavenclad
20 Feb 2025 19:28 GMT
… share her experiences through EMD Serono’s ongoing “I’m Ready … Mavenclad’s FDA approval. The campaign kicked off with EMD Serono’s …
-
PARP Inhibitors Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
12 Feb 2025 12:35 GMT
PARP Inhibitors Pipeline
LAS VEGAS, NV, UNITED STATES, February 12, 2025 /EINPresswire.com/ -- DelveInsight’s, “PARP Inhibitors Pipeline Insight” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in PARP …
-
Human Microbiome Based Drugs Diagnostics Market Growth at a CAGR of 19.03% to Hit 85.7 Billion USD by 2032 | EMD Serono
31 Jan 2025 07:40 GMT
… 2032. Expansion in precision medicine, FDA approval of microbiome-based therapies … Pharmaceuticals
4D pharma
Clostridium
EMD Serono
Danone
AkesoBiome
Nestle
GITherapeutics
Get …
-
FDA Approved Drug Products Approval List November 2024
17 Dec 2024 07:53 GMT
Approval Date Drug Name Submission Active Ingredients Company Submission Classification * Submission Status 11/01/2024 BYETTANDA #021773 SUPPL-49 EXENATIDE SYNTHETIC ASTRAZENECA AB Labeling Approval 11/01/2024 BYDUREONNDA #022200 SUPPL- …
-
Dr Janjigian on the FDA Approval of Zolbetuximab for CLDN18.2+ Gastric/GEJ Adenocarcinoma
23 Nov 2024 16:29 GMT
… , discusses the significance of the FDA approval of zolbetuximab-clzb (Vylov … .
On October 18, 2024, the FDA approved zolbetuximab in combination with … , Master Clinician Alliance, Merck, Merck Serono, Mersana Therapeutics, Michael J. Hennessy …
-
FDA Approves Companion Diagnostic for Tepotinib in mNSCLC Harboring MET Exon 14 Skipping Alterations
18 Nov 2024 19:36 GMT
… ;resources-information-approved-drugs/fda-approves-tepotinib-metastatic-non-small … ;resources-information-approved-drugs/fda-grants-accelerated-approval-tepotinib-metastatic … Serono; 2023. Accessed November 18, 2024. https://www.accessdata.fda …
-
2024 Updates in GI Cancer Feature FLOT Combinations, Restricted FDA Approvals by PD-L1 Expression, and More
15 Nov 2024 01:15 GMT
… Master Clinician Alliance, Merck, Merck Serono, Mersana Therapeutics, Michael J. Hennessy … pembrolizumab’s gastric cancer indication. FDA. Updated November 8, 2023. … resources-information-approved-drugs/fda-amends-pembrolizumabs-gastric-cancer-indication …
-
Non-Small Cell Lung Cancer Pipeline Dynamics 2024: FDA Approvals, Therapies, MOA, ROA, And Developments | Abbvie, Xcovery, Sanofi, Pfizer, Mirati Therapeutics, Astrazeneca, Daiichi Sankyo, Merck Sharp
18 Oct 2024 15:59 GMT
… ., Ono Pharmaceutical Co. Ltd, EMD Serono, Incyte Corporation, Eisai Inc., Parexel … therapy.
In February 2024, The FDA has granted breakthrough therapy designation … Pharmaceutical Co. Ltd
M7824: EMD Serono
Retifanlimab: Incyte Corporation
Lenvatinib: Eisai …
About
© 1995-2025